Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

News

41 - 50of about 630 News

41 - 50of about 630 News

November 13, 2020

Not intended for U.S. and UK Media

Positive CHMP opinion for extension of rivaroxaban marketing authorization to treat venous thromboembolism (VTE) in children

November 12, 2020

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 09, 2020

Not intended for U.S. and UK Media

Bayer submits marketing authorization applications for finerenone in the U.S. and the EU for patients with chronic kidney disease and type 2 diabetes

November 03, 2020

Bayer:

Challenging third quarter – Group outlook confirmed

October 27, 2020

The U.S. EPA announces new 5-year registration for XtendiMax® herbicide, Bayer’s low-volatility dicamba product

October 27, 2020

Bayer appoints Dr. Christian Rommel as new Head of Pharmaceuticals Research and Development

October 26, 2020

Bayer acquires Asklepios BioPharmaceutical to broaden innovation base in cell and gene therapy

October 23, 2020

Not intended for U.S. and UK Media

FDA approves FoundationOne®CDx as companion diagnostic for Vitrakvi™ (larotrectinib) to aid in identifying NTRK fusion-positive patients

October 23, 2020

Not intended for U.S. and UK Media – Data from Phase III FIDELIO-DKD study presented at the American Society of Nephrology (ASN)’s Kidney Week 2020

Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

October 14, 2020

Not intended for U.S. and UK Media

Combination of copanlisib and rituximab significantly prolonged progression-free survival of patients with relapsed indolent non-Hodgkin's Lymphoma

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases